文献速递心血管US

达格列净对心力衰竭患者心脏变形及次要临床结局的影响

Dapagliflozin Effects on Cardiac Deformation in Heart Failure and Secondary Clinical Outcome.
PubMed 文献 · JACC Cardiovasc Imaging · 2024-07-17

这项随机、前瞻性、单中心、开放标签试验纳入88例非糖尿病HFrEF或HFmrEF门诊患者,比较在优化药物治疗基础上加用达格列净与单用优化药物治疗6个月后斑点追踪超声心动图参数的变化。达格列净组所有斑点追踪超声心动图参数均改善,优化药物治疗组改善不显著,两组间主要治疗效应差异有统计学意义(P < 0.0001)。

要点

  • 达格列净组6个月时左室整体纵向应变、左房纵向应变及右室功能均改善,优化药物治疗组改善不显著。
  • HFrEF与HFmrEF患者中仅主要治疗效应差异有统计学意义(P < 0.0001)。
  • 斑点追踪超声心动图可用于评估达格列净对非糖尿病心衰患者心肌性能的影响。

核心结论

  • 在非糖尿病HFrEF和HFmrEF患者中,达格列净在优化药物治疗基础上加用6个月可改善斑点追踪超声心动图测量的心肌性能,提示其可能有助于左室逆重构和改善生活质量。

研究设计与样本

  • 随机、前瞻性、单中心、开放标签试验,纳入连续非糖尿病HFrEF或HFmrEF门诊患者88例(38%为HFmrEF),随机分为达格列净组(n = 44,在优化药物治疗基础上加用达格列净)和优化药物治疗组(n = 44,继续优化药物治疗但不用SGLT2抑制剂);主要终点为基线至6个月斑点追踪超声心动图测量的左室整体纵向应变、舒张功能(左房纵向应变峰值)和右室功能的显著改变;心血管事件和充血参数作为安全性探索性终点。

诊断标准与关键数值

  • 主要终点为基线至6个月左室整体纵向应变、左房纵向应变峰值(舒张功能)和右室功能经斑点追踪超声心动图的显著改变。
  • 随访6个月时达格列净组所有斑点追踪超声心动图参数均改善,优化药物治疗组改善不显著。
  • 比较HFrEF和HFmrEF患者随访时斑点追踪超声心动图参数的变化,仅主要治疗效应在两组中均有统计学意义(P < 0.0001),表明达格列净与优化药物治疗之间存在显著差异。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors were shown to reduce morbidity and mortality in patients with heart failure.

OBJECTIVES: This study aims to assess potential effects of dapagliflozin in nondiabetic patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with mildly reduced ejection fraction (HFmrEF) on cardiac function assessed by speckle tracking echocardiography (STE).

METHODS: This randomized, prospective, single-center, open-label trial compared consecutive nondiabetic outpatients with HFrEF or HFmrEF receiving dapagliflozin with patients treated with optimal medical therapy (OMT) except sodium-glucose cotransporter type 2 inhibitors. Primary endpoint was the presence of a significant modification of left ventricular global longitudinal strain, diastolic function (as peak atrial longitudinal strain) and right ventricular function by STE from baseline to 6 months. Cardiovascular events and parameters of congestion were assessed as safety-exploratory endpoints.

RESULTS: Overall, 88 patients (38% HFmrEF) were enrolled and randomized to start dapagliflozin on top of OMT (n = 44) or to continue with OMT (n = 44). All STE values improved in the dapagliflozin group after 6 months, whereas there was a nonsignificant improvement in OMT group. Moreover, when comparing the modification of STE parameters at follow-up in patients with HFrEF and HFmrEF, only the main treatment effect resulted statistically significant in both groups (P < 0.0001), indicating a significant difference between dapagliflozin and OMT.

CONCLUSIONS: This study provided randomized data on the beneficial effect of dapagliflozin in nondiabetic patients with HFrEF and HFmrEF in terms of myocardial performance measured by the most sensitive echocardiographic technique, ie, STE. This suggests its usefulness for left ventricular reverse remodeling and better quality of life in patients with HFrEF and HFmrEF. (Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fraction [DAPA ECHO trial]; EudraCT number: 2021-005394-66).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Pastore MC, Stefanini A, Mandoli GE, et al. Dapagliflozin Effects on Cardiac Deformation in Heart Failure and Secondary Clinical Outcome. JACC Cardiovasc Imaging. 2024. PMID: 39023499. doi:10.1016/j.jcmg.2024.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。